Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Potassium chloride, Sodium chloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
e Potassium 0.15 & Sodium 0.9 Infusion 3. How to use Potassium 0.15 & Sodium 0.9 Infusion 4. Possible side effects 5. How to store Potassium 0.15 & Sodium 0.9 Infusion 6. Content of the pack and other information
You must NOT receive Potassium 0.15 & Sodium 0.9 Infusion if you are suffering from any of the following conditions: •
• •
1. WHAT POTASSIUM 0.15 & SODIUM 0.9 INFUSION IS AND WHAT IT IS USED FOR
• •
Potassium 0.15 & Sodium 0.9 Infusion is a solution of potassium chloride and sodium chloride in water. Potassium chloride and sodium chloride are chemical substances (often called "salts") found in the blood. Potassium 0.15 & Sodium 0.9 Infusion is used to prevent and treat:
•
•
1
if you are allergic to potassium chloride and sodium chloride or any other ingredients of this medicine (listed in section 6) higher levels of potassium in the blood than normal (hyperkalaemia) higher levels of chloride in the blood than normal (hyperchloraemia) higher levels of sodium in the blood than normal (hypernatraemia) severe kidney failure (when your kidneys do not work well and you require dialysis) uncompensated heart failure. This is heart failure that is not adequately treated and causes symptoms such as:
death. Brain swelling increases the risk of death and brain damage. People who are at higher risk of brain swelling are:
Warning and precautions Potassium 0.15 & Sodium 0.9 Infusion is a hypertonic (concentrated) solution. Your doctor will take this into account when calculating how much solution to give you. Please tell your doctor if you have or have had any of the following medical conditions.
Your doctor will take into account if you are receiving parenteral nutrition (nutrition given by infusion into a vein). During long term treatment with Potassium 0.15 & Sodium 0.9 Infusion you may need to be given extra nutrition.
Other medicines and Potassium 0.15 & Sodium 0.9 Infusion Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. It is particularly important that you inform your doctor if you are taking:
Driving and using machines
–
• •
•
medicines that contain potassium (e.g. potassium supplements, salt substitutes containing potassium) corticosteroids (anti-inflammatory medicines). some medicines act on the hormone vasopressin. These may include:
Potassium 0.15 & Sodium 0.9 Infusion does not affect your ability to drive or use machines.
POTASSIUM 0.15 & SODIUM 0.9 INFUSION Potassium 0.15 & Sodium 0.9 Infusion will be given to you by a doctor or nurse. Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, clinical and biological conditions and state of hydration (the amount of water in your body). The amount you are given may also be affected by other treatments you are receiving.
You should NOT be given Potassium 0.15 & Sodium 0.9 Infusion if there are particles floating in the solution or if the pack is damaged in any way. The speed of infusion will be decided by your doctor. If you require a large volume or rapid infusion of Potassium 0.15 & Sodium 0.9 Infusion, your doctor may monitor your ECG (heart tracing). Potassium 0.15 & Sodium 0.9 Infusion will usually be given to you through a plastic tube attached to a needle in a vein. Usually a vein in your arm is used to give you the infusion. However, your doctor may use another method to give you the medicine. Before and during the infusion, your doctor will monitor
Potassium 0.15 & Sodium 0.9 Infusion with food and drink You should ask your doctor about what you can eat or drink.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine. Tell your doctor if you are pregnant or breast-feeding.
If you suffer from poor kidney function, you may receive a lower dose. Any unused solution should be thrown away. You should NOT be given an infusion of Potassium 0.15/ & Sodium 0.9 Infusion from a bag that has been partly used.
Potassium 0.15 & Sodium 0.9 Infusion can be given during pregnancy. The amount you are given must be carefully controlled by your doctor. If another medicine is to be added to your solution for infusion during pregnancy or breast-feeding you should:
TH-30-02-214 3
If you take more Potassium 0.15 & Sodium 0.9 Infusion than you should
•
If you are given too much Potassium 0.15 & Sodium 0.9 Infusion (over-infusion), this may lead to the following symptoms:
•
•
• • • •
If you develop any of these symptoms you must inform your doctor immediately. Your infusion will be stopped and you will be given treatment depending on the symptoms.
•
If a medicine has been added to your Potassium 0.15 & Sodium 0.9 Infusion before over-infusion occurs, that medicine may also cause symptoms. You should read the Package Leaflet of the added medicine for a list of possible symptoms.
•
irritation and inflammation of the vein into which the solution is infused (phlebitis). This can cause redness, pain or burning and swelling along the path of the vein into which the solution is infused. the formation of a blood clot (venous thrombosis) at the site of infusion, which causes pain, swelling or redness in the area of the clot escape of the infusion solution into the tissues around the vein (extravasation). This can damage the tissues and cause scarring. an excess of fluid in the blood vessels (hypervolaemia) any allergic reaction increase levels of potassium in the blood (hyperkalemia) Low levels of sodium in the blood that may be acquired during hospitalization (nosocomial hyponatraemia) and related neurological disorder (acute hyponatraemic encephalopathy). Hyponatraemia can lead to irreversible brain injury and death due to cerebral oedema/swelling (see also in the section 2 "Warnings and precautions"). high chloride level in blood or low bicarbonate levels in blood (acidosis hyperchloremic) cardiac arrest.
If a medicine has been added to the solution for infusion, the added medicine may also cause side effects. These side effects will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.
If you stop taking your Potassium 0.15 & Sodium 0.9 Infusion Your doctor will decide when to stop giving you this infusion.
Please tell your doctor or nurse if you notice any listed or unlisted side effects. If any side effects occur, the infusion must be stopped.
If you have any further questions on the use of this product, ask your doctor.
Reporting of side effects If you get any side effects talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the following routes:
Like all medicines, Potassium 0.15 & Sodium 0.9 Infusion can cause side effects, although not everybody gets them. The side effects that may occur
United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
TH-30-02-214 4
Ireland HPRA Pharmacovigilance Website: www.hpra.ie
The bags are supplied in cartons. Each carton contains one of the following quantities:
Malta ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal
Not all pack sizes may be marketed Marketing Authorisation Holder and Manufacturers Marketing Authorisation Holder for the United Kingdom: Baxter Healthcare Ltd Caxton Way, Thetford, Norfolk, IP24 3SE United Kingdom
By reporting side effects you can help provide more information on the safety of this medicine.
POTASSIUM 0.15 & SODIUM 0.9 INFUSION
Marketing Authorisation Holder for Ireland and Malta: Baxter Holding B.V. Kobaltweg 49, 3542CE Utrecht, Netherlands
Keep out of the reach and sight of children. Potassium 0.15 & Sodium 0.9 Infusion does not require special storage conditions. Potassium 0.15 & Sodium 0.9 Infusion should NOT be given to you after the expiry date which figures on the bag. The expiry date refers to the last day of that month.
Manufacturers for Great Britain: Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium
You should not be given Potassium 0.15 & Sodium 0.9 Infusion, if there are particles floating in the solution or if the unit is damaged in any way.
Baxter Healthcare Ltd. Caxton Way, Thetford Norfolk IP24 3SE United Kingdom
6. CONTENT OF THE PACK AND OTHER INFORMATION What Potassium 0.15 & Sodium 0.9 Infusion contains
Bieffe Medital Sabiñanigo Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
The active substances are:
Manufacturers for Ireland: Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium
The only other ingredient is water for injections
What Potassium 0.15 & Sodium 0.9 Infusion looks like and contents of the pack
Bieffe Medital Sabiñanigo Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
Potassium 0.15 & Sodium 0.9 Infusion is a clear solution, free from visible particles. It is supplied in polyolefin/polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch. The bag sizes are:
This leaflet was last revised in June 2023 For information about Potassium 0.15 & Sodium 0.9 Infusion or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder: Tel: +44 (0)1635 206345. TH-30-02-214 5
Baxter and Viaflo are trademarks of Baxter International lnc. TH-30-02-214 6
Potassium Chloride 0.15 % w/v & Sodium Chloride 0.9% w/v Solution for Infusion BP The following information is intended for medical or healthcare professionals only:
b. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. c. Check the solution for limpidity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.
Handling and Preparation Use only if the solution is clear, without visible particles and if the container is undamaged. Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product. Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. Additives may be introduced before infusion or during infusion through the re-sealable medication port. When additive is used, verify isotonicity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored. After addition, if there is a colour change and/or the appearance of precipitates, insoluble complexes or crystals, do not use.
2. Preparation for administration Use sterile material for preparation and administration. a. Suspend container from eyelet support. b. Remove plastic protector from outlet port at bottom of container:
3. Techniques for injection of additive medications The solution should not be administered in the atrium or ventricle to avoid localised hyperkalaemia, but in large peripheral or central vein to diminish the risk of causing sclerosis. Warning: Additives may be incompatible (see paragraph 5 "Incompatibilities of additive medications" below).
Adding medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. In case of adverse reaction, infusion must be stopped immediately.
To add medication before administration a. Disinfect medication port . b. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix.
Discard after single use. Discard any unused portion. Do not reconnect partially used bags.
1. Opening a. Remove the Viaflo container from the overpouch just before use.
TH-30-02-214 7
Caution: Do not store bags containing added medications. To add medication during administration a. Close clamp on the set b. Disinfect medication port . c. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. d. Remove container from IV pole and/or turn to an upright position. e. Evacuate both ports by tapping gently while the container is in an upright position. f. Mix solution and medication thoroughly. g. Return container to in use position, re-open the clamp and continue administration
4. In-use shelf life (Additives) Chemical and physical stability of any additive medication at the pH of the Potassium 0.15& Sodium 0.9 Infusion in the Viaflo container should be established prior to use. From a microbiological point of view, the diluted product must be used immediately unless dilution has taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions are the responsibility of the user.
5. Incompatibilities of additive medications As with all parenteral solutions, incompatibility of the additive medications with the solution must be assessed before addition. In the absence of compatibility studies, this solution must not be mixed with other medicinal products. It is the responsibility of the physician to judge the incompatibility of an additive medication with the Potassium 0.15 & Sodium 0.9 Infusion, by checking for eventual colour change and/or eventual appearance of precipitate, insoluble complexes or crystals. The Instructions for Use of the medication to be added must be consulted. Before adding a drug, verify it is soluble and/or stable in water at the pH of the Potassium 0.15 & Sodium 0.9 Infusion (pH: 4.5 to 7.0). Those additives known to be incompatible should not be used.
Baxter and Viaflo are trademarks of Baxter International lnc. TH-30-02-214 8
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Potassium Chloride 0.15 % w/v & Sodium Chloride 0.9% w/v Solution for Infusion is indicated for the prevention and treatment of potassium depletion and/or hypokalaemia, in sodium chloride and water-losing conditions.
Posology
Adults, the Elderly, Adolescents and Children
Fluid balance, serum electrolytes and acid-base balance should be monitored before and during administration, with particular attention to serum sodium in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs, due to the risk of hospital acquired hyponatraemia (see sections 4.4, 4.5 and 4.8). Monitoring of serum sodium is particularly important for hypotonic fluids.
Potassium Chloride 0.15% & Sodium Chloride 0.9% Solution for Infusion has a tonicity of 348 mOsm/l (approx.)
The infusion rate and volume depend on the age, weight, clinical condition (e.g. burns, surgery, head-injury, infections), and concomitant therapy should be determined by the consulting physician experienced in paediatric intravenous fluid therapy (see sections 4.4. and 4.8).
Doses may be expressed in terms of mEq or mmol of each cation, mass of each cation, or mass of each cation salt:
- for sodium
1 g NaCl = 394 mg of Na+ or 17.1 mEq or 17.1 mmol of Na+ and Cl-
1 mmol Na+ = 23mg Na+
- for potassium
1 g KCl = 525 mg of K+ or 13.4 mEq or 13.4 mmol of K+ and Cl-
1 mmol K+ = 39.1 mg K+
Posology for prevention and treatment of potassium depletion
- For Adults, the Elderly and Adolescents:
Typical dose of potassium for the prevention of hypokalaemia may be up to 50 mmoles daily and similar doses may be adequate in mild potassium deficiency.
When used for treatment of hypokalaemia, the recommended dosage is 20 mmoles of potassium over 2 to 3 hours (i.e. 7-10 mmol/h) under ECG control.
The maximum recommended administration rate should not exceed 15-20 mmol/h.
Patient with renal impairment should receive lower doses.
- Use in Paediatric Population (28 days to 11 years):
The maximal recommended dose of potassium is 2 to 3 mmol/kg bw/day.
Method of Administration
The administration is performed by intravenous route using sterile and non-pyrogenic equipment.
Intravenous potassium should be administered in a large peripheral or central vein to diminish the risk of causing sclerosis. If infused through central vein, be sure the catheter is not in the atrium or ventricle to avoid localized hyperkalaemia.
The osmolarity of a final admixed infusion solution must be taken into account when peripheral administration is considered.
Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, clinically significant hyperosmolar solutions are recommended to be administered through a large central vein, for rapid dilution of the hyperosmolar solution.
Additional electrolyte supplementation may be indicated according to the clinical needs of the patient. When introducing additives to Potassium chloride 0.15% w/v & Sodium Chloride 0.9% w/v solution for infusion, the instructions for use of the medication to be added and other relevant literature must be consulted (see also Special precautions for disposal and other handling, section 6.6).
Risk of air embolism
Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Rate of administration
Solution containing potassium should be administered slowly. As administered intravenously, potassium should not be given faster than 15 to 20 mmoles/h to avoid a dangerous hyperkalaemia. Rapid correction of hyponatremia and hypernatremia is potentially dangerous (risk of serious neurological complications) (see also Special Warnings and precautions for Use; section 4.4).
Monitoring
Adequate urine flow must be ensured and careful monitoring of plasma-potassium and other electrolyte concentrations is essential. High dosage or high speed infusion must be performed under ECG control.
The Potassium chloride 0.15 % w/v & Sodium Chloride 0.9% w/v solution for infusion is contra-indicated in patients with:
- known hypersensitivity to the product
- documented hyperkalaemia, hyperchloraemia or hypernatraemia
- severe renal insufficiency (with oliguria/anuria)
- uncompensated cardiac failure
- Addison's disease
Potassium chloride 0.15% w/v & Sodium chloride 0.9% w/v Solution for Infusion is a hypertonic solution.
Hypersensitivity reactions:
- Hypersensitivity/infusion reactions, including anaphylaxis, have been reported with other products containing potassium chloride and sodium chloride.
- Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Risk of serum electrolytes and water imbalance
Depending on the volume and rate of infusion and depending on a patient's underlying clinical condition, intravenous administration of Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for infusion can cause:
electrolyte disturbances such as
- Hypernatremia,
- Hyponatremia (see use in patients at risk for sodium imbalance).
acid−base imbalance.
overhydration/hypervolemia and, for example, congested states, including central (e.g., pulmonary congestion) and peripheral edema.
Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid−base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.
High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatraemia (see below).
Hyponatraemia
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (cerebral oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with cerebral oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, cerebral contusion and brain oedema) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.
Potassium salts should be administered with considerable care to patients with cardiac disease or conditions predisposing to hyperkalaemia such as renal or adrenocortical insufficiency, acute dehydration, or extensive tissue destruction as occurs with severe burns. In patients under digitalis therapy, regular monitoring of the plasma potassium level is mandatory.
Sodium salts should be administered with caution to patients with hypertension, heart failure, peripheral or pulmonary oedema, impaired renal function, pre-eclampsia, or other conditions associated with sodium retention (see also Section 4.5 − Interactions with other medicinal products and other forms of interaction).
Pediatric use
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy, and should be determined by a physician experienced in pediatric intravenous fluid therapy.
Elderly use
When selecting the type of infusion solution and the volume/rate of infusion for an elderly patient, consider that elderly patients are generally more likely to have cardiac, renal, hepatic, and other diseases and/or concomitant drug therapy.
Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be increased during administration of Potassium Chloride 0.15 %w/v & Sodium chloride 0.9% w/v Solution for infusion and this can result in decreased lithium levels.
Potassium Chloride 0.15 %w/v & Sodium chloride 0.9% w/v Solution for infusion should be used with caution in patients treated concurrently or recently with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as medicinal products that contains potassium, potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants cyclosporine and tacrolimus.
Administration of potassium in patients treated with such agents is associated with an increased risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia.
Potassium Chloride 0.15 %w/v & Sodium chloride 0.9% w/v Solution for infusion should be used with particular caution in patients on concomitant medications that may increase the risk of sodium and fluid retention, such as corticosteroids.
Drugs leading to an increased vasopressin effect
The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).
▪ Drugs stimulating vasopressin release include: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics
▪ Drugs potentiating vasopressin action include: Chlorpropamide, NSAIDs, cyclophosphamide
▪ Vasopressin analogues include: Desmopressin, oxytocin, terlipressin
Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
There are no adequate data from the use of Potassium chloride 0.15% w/v & Sodium chloride 0.9% w/v solution for infusion in pregnant or lactating women.
Physician should carefully consider the potential risks and benefits for each specific patient before administering Potassium chloride 0.15% w/v & Sodium chloride 0.9% w/v solution for infusion.
Potassium chloride 0.15% & Sodium chloride 0.9% solution should be administrated with special caution for pregnant women during labour, particularly as to serum-sodium if administered in combination with oxytocin (see section 4.4, 4.5 and 4.8).
There is no information on the effects of Potassium Chloride 0.15% w/v & Sodium chloride 0.9% w/v solution for infusion on the ability to operate automobile or other heavy machinery.
The following adverse reactions have been reported spontaneously during Post-Marketing use of the product. The frequencies cannot be estimated due to the nature of the data.
System Organ Class (SOC)
MedDRA Preferred Term
Infections and infestations
Injection site infection(1)
Metabolism and nutrition disorders
Hypervolemia(1)
Hospital acquired hyponatraemia(2)
Nervous system disorders
Acute hyponatraemic encephalopathy(2)
General disorders and administration site conditions
Extravasation(1)
Injection site irritation(1)
Injection site pain(1)
Injection site phlebitis(1)
Injection site reaction(1)
Injection site thrombosis(1)
Pyrexia(1)
(1) Adverse reactions that may be associated to the technique of administration
(2)Hospital acquired hyponatraemia may cause irreversible brain injury and death, due to development of acute hyponatraemic encephalopathy, frequency unknown (see sections 4.2. 4.4, 4.5).
Others adverse reactions reported with other potassium chloride and sodium chloride formulations include:
hypersensitivity, hyperkalemia, acidosis hyperchloremic, cardiac arrest as a manifestation of rapid intravenous administration and/or of hyperkalemia.
In case of undesirable effect(s), the infusion must be discontinued.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Health care professionals are asked to report any suspected adverse reactions via:Yellow Card SchemeWebsite: www.mhra.gov.uk/yellowcard
Excessive administration of Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion can cause:
hyperkalemia, manifestations of hyperkalemia may include:
• disturbance in cardiac conduction and arrhythmias, including bradycardia, heart block, asystole, ventricular tachycardia, ventricular fibrillation.
• hypotension,
• muscle weakness up to and including muscular and respiratory paralysis, paresthesia of extremities,
• gastrointestinal symptoms (ileus, nausea, vomiting, abdominal pain)
Among the important indicators of potassium toxicity are ECG changes, including tall, peaked T-waves, depression of S-T segment, disappearance of the P-wave, prolongation of the Q-T interval, and widening and slurring of the QRS complex.
Retention of excess sodium when there is a defective renal sodium excretion may result in pulmonary and peripheral oedema.
Excessive administration of chloride salts may cause a loss of bicarbonate with an acidifying effect.
See also section 4.3, 4.4 and 4.8
When assessing an overdose, any additives in the solution must be considered.
The effect of an overdose may require immediate medical attention and treatment.
Treatment of hyperkalaemia involves the administration of calcium, insulin or sodium bicarbonate, and exchange resins or dialysis.
Interventions include discontinuation of Potassium chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for infusion administration, dose reduction and other measures as indicated for the specific clinical constellation.
Ask anything about Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion – BP. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.